Cytek Biosciences (CTKB) Other Accumulated Expenses (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Other Accumulated Expenses data on file, last reported at $22.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 72.74% year-over-year to $22.2 million; the trailing twelve-month figure through Mar 2026 stood at $22.2 million (up 72.74% YoY), and the FY2025 full-year result was $17.0 million, up 25.82% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $22.2 million, up from $17.0 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $22.2 million in Q1 2026 and bottomed at $4.9 million in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $8.4 million (2023), against an average of $10.8 million.
• The widest annual swing landed in 2022, when Other Accumulated Expenses surged 316.73%; it then dropped 24.24% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $8.0 million in 2022, then fell by 0.72% to $7.9 million in 2023, then soared by 70.75% to $13.5 million in 2024, then gained by 25.82% to $17.0 million in 2025, then soared by 30.6% to $22.2 million in 2026.
• The last three Other Accumulated Expenses figures came in at $22.2 million (Q1 2026), $17.0 million (Q4 2025), and $16.4 million (Q3 2025), per Business Quant data.

Peer Comparison